Phase 1 Mesothelioma Clinical Trials
43 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 43 trials
Recruiting
Phase 1
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
University Hospital, Antwerp15 enrolled3 locationsNCT05765084
Recruiting
Phase 1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 1Phase 2
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Perspective Therapeutics112 enrolled8 locationsNCT06710756
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Ovarian CancerMesothelioma, MalignantCholangiocarcinoma Recurrent
Verismo Therapeutics42 enrolled5 locationsNCT05568680
Recruiting
Phase 1
SW-682 in Advanced Solid Tumors
Advanced Solid TumorMesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany186 enrolled8 locationsNCT06251310
Recruiting
Phase 1Phase 2
A 2-part Phase 1/2 Open-label Trial on ODM-212
Pancreatic CancerMesotheliomaNSCLC (Advanced Non-small Cell Lung Cancer)
Orion Corporation, Orion Pharma229 enrolled2 locationsNCT07563738
Not Yet Recruiting
Phase 1
A Phase 1a/1b Dose-Escalation and Expansion Study of [¹77Lu]Lu-FAP-2286 Radioligand Therapy in Combination with Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Patients with Unresectable or Advanced Malignant Pleural Mesothelioma (MPM)
Malignant Pleural Mesothelioma
South Metropolitan Health Service50 enrolled2 locationsACTRN12626000505303
Recruiting
Phase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Colorectal, CancerOvarian CancerPeritoneal Carcinomatosis+4 more
National Cancer Institute (NCI)60 enrolled1 locationNCT04847063
Recruiting
Phase 1
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Urothelial CarcinomaDiffuse Pleural MesotheliomaGastroesophageal Carcinoma
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07532902
Recruiting
Phase 1Phase 2
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Pleural Effusion, MalignantMalignant MesotheliomaMalignant Pleural Effusion+1 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)10 enrolled1 locationNCT07443020
Recruiting
Phase 1
A Study of VET3-TGI in Patients With Solid Tumors
Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 1Phase 2
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Malignant Pleural Mesotheliomas
Beijing Biotech36 enrolled1 locationNCT07510815
Recruiting
Phase 1Phase 2
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NSCLCSolid Tumor, AdultMesothelioma
Vivace Therapeutics, Inc434 enrolled12 locationsNCT04665206
Recruiting
Phase 1Phase 2
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Advanced Renal Cell CarcinomaAdvanced MesotheliomaAdvanced Osteosarcoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT05703854
Recruiting
Phase 1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Advanced Solid TumorMesotheliomaRenal Cancer+3 more
Nuvectis Pharma, Inc.140 enrolled12 locationsNCT05873686